Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › ROR1 (NTRKR1) specific chimeric antigen receptors for cancer immunotherapy

ROR1 (NTRKR1) specific chimeric antigen receptors for cancer immunotherapy

US Patent 10752684 · Granted Aug 25, 2020

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Trophoblast glycoprotein (5T4, TPBG) specific chimeric antigen receptors for can2024
Universal chimeric antigen receptor T cells specific for CD222023
Methods for engineering highly active T cell for immunotherapy2022
Methods for engineering allogeneic and highly active t cell for immunotherapy2022
CD19 specific chimeric antigen receptor and uses thereof2021
CD19 specific chimeric antigen receptor and uses thereof2021
CD19 specific chimeric antigen receptor and uses thereof2020
Trophoblast glycoprotein (5T4, TPBG) specific chimeric antigen receptors for can2020
Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy2020
ROR1 specific multi-chain chimeric antigen receptor2020